DeepMed Research

AFM-24

Generic Name: AFM-24

Clinical Trials

Study to Assess AFM24 in Combination with Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: AFM24
Drug: Atezolizumab 840 MG in 14 ML Injection

First Posted Date: 2021-11-05

Last Posted Date: 2024-10-02

Lead Sponsor: Affimed GmbH

Target Recruit Count: 148

Registration Number: NCT05109442

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇵🇱
Independent Public Teaching Hospital #4 in Lublin, Department of Clinical Oncology and Chemotherapy, Lublin, Poland

and more 13 locations

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

Phase 1

Terminated

Conditions: Squamous Cell Carcinoma of Head and Neck
Carcinoma, Non-Small-Cell Lung
Colorectal Neoplasms
Advanced Solid Tumor
Refractory Tumor
Metastatic Tumor

Interventions: Drug: AFM24
Biological: SNK01

First Posted Date: 2021-10-29

Last Posted Date: 2024-03-01

Lead Sponsor: NKGen Biotech, Inc.

Target Recruit Count: 11

Registration Number: NCT05099549

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy